ResMed Inc. (NYSE:RMD) Shares Bought by Atria Investments Inc

Atria Investments Inc raised its position in ResMed Inc. (NYSE:RMD) by 21.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,106 shares of the medical equipment provider’s stock after purchasing an additional 372 shares during the quarter. Atria Investments Inc’s holdings in ResMed were worth $482,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of RMD. Apollon Wealth Management LLC boosted its holdings in ResMed by 15.1% in the 3rd quarter. Apollon Wealth Management LLC now owns 1,451 shares of the medical equipment provider’s stock valued at $354,000 after purchasing an additional 190 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of ResMed in the 3rd quarter worth approximately $410,000. Victory Capital Management Inc. lifted its holdings in shares of ResMed by 11.4% in the 3rd quarter. Victory Capital Management Inc. now owns 116,710 shares of the medical equipment provider’s stock worth $28,491,000 after acquiring an additional 11,914 shares during the last quarter. Huntington National Bank lifted its holdings in shares of ResMed by 6.9% in the 3rd quarter. Huntington National Bank now owns 1,868 shares of the medical equipment provider’s stock worth $456,000 after acquiring an additional 120 shares during the last quarter. Finally, KBC Group NV lifted its holdings in shares of ResMed by 255.3% in the 3rd quarter. KBC Group NV now owns 72,731 shares of the medical equipment provider’s stock worth $17,756,000 after acquiring an additional 52,259 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Trading Up 2.2 %

Shares of NYSE:RMD opened at $224.48 on Friday. ResMed Inc. has a 52 week low of $172.19 and a 52 week high of $263.05. The company’s 50 day moving average is $236.30 and its two-hundred day moving average is $239.82. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a market cap of $32.97 billion, a PE ratio of 26.50, a P/E/G ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, beating analysts’ consensus estimates of $2.29 by $0.14. ResMed had a net margin of 25.34% and a return on equity of 26.17%. Equities analysts predict that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be paid a dividend of $0.53 per share. The ex-dividend date is Thursday, February 13th. This represents a $2.12 annualized dividend and a yield of 0.94%. ResMed’s dividend payout ratio is currently 25.03%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. upped their price objective on shares of ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. UBS Group upgraded shares of ResMed from a “hold” rating to a “strong-buy” rating in a report on Friday, January 31st. Needham & Company LLC restated a “hold” rating on shares of ResMed in a report on Friday, January 31st. The Goldman Sachs Group initiated coverage on shares of ResMed in a report on Thursday, January 16th. They issued a “buy” rating on the stock. Finally, Citigroup upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $243.82.

Insider Buying and Selling

In related news, insider Kaushik Ghoshal sold 9,113 shares of ResMed stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $235.40, for a total transaction of $2,145,200.20. Following the sale, the insider now directly owns 9,725 shares in the company, valued at $2,289,265. This trade represents a 48.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $227.71, for a total transaction of $455,420.00. Following the sale, the director now owns 75,218 shares in the company, valued at $17,127,890.78. This represents a 2.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,940 shares of company stock worth $9,164,385 in the last ninety days. 0.71% of the stock is owned by corporate insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.